Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 881 / https://doi.org/10.3332/ecancer.2018.881

Short Communication

Learning from the past to design better trials in second-line treatment for mesothelioma patients

Malignant pleural mesothelioma (MPM) is an aggressive cancer characterised by modest sensitivity to systemic chemotherapy. The standard treatment remains platinum-based chemotherapy with pemetrexed. Recently, the addition of an antiangiogenic drug, bevacizumab, to first-line chemotherapy has been shown to improve overall survival. All the patients, unfortunately, will progress, and currently, there is no standard treatment approved in second-line. Recently, the results of the NGR015 phase III randomised with NGR-hTNF plus chemotherapy versus placebo in addition to physician’s choice second-line chemotherapy for MPM have been published. Despite encouraging data achieved in previous phase I and phase II studies, the NGR-hTNF drug failed to meet the primary endpoint of the study, although a signal of activity was observed in the group of patients who had a shorter treatment failure interval from the first-line treatment.

Hereby, we start from this recent trial to highlight once more the importance of thoroughly investigating possible predictive factors during the early drug development phase to allow more efficient phase III trial design, thus avoiding the possibility of potentially effective molecules like NGR-hTNF, continuing to be wasted.

Keywords: Mesothelioma, trial design, angiogenesis

Categories:

Lung & pleura

Loading Article Metrics ... Please wait

Related articles

Research: ReDO_DB: the repurposing drugs in oncology database

Abstract | Full Article | PDF Published: 06 Dec 2018 / https://doi.org/10.3332/ecancer.2018.886

Review: Fertility preservation in ovarian tumours

Abstract | Full Article | PDF Published: 06 Dec 2018 / https://doi.org/10.3332/ecancer.2018.885

Research: Detection of precancerous lesions in the cervix and HPV infection in women in the region of Maniapure, Bolivar State

Abstract | Full Article | PDF | Spanish Published: 03 Dec 2018 / https://doi.org/10.3332/ecancer.2018.884

Review: Targeted literature review of the global burden of gastric cancer

Abstract | Full Article | PDF Published: 26 Nov 2018 / https://doi.org/10.3332/ecancer.2018.883

Case Report: Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation

Abstract | Full Article | PDF | Spanish Published: 20 Nov 2018 / https://doi.org/10.3332/ecancer.2018.882



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation